Ysios Capital’s portfolio company Adcendo announces extension of Series A financing to 82M€ to ensure broad development of first-in-class ADC pipeline 

Inversión, Tecnología, Venture Capital

04/04/2023 Nota de prensa YSIOS CAPITAL’S PORTFOLIO COMPANY ADCENDO ANNOUNCES EXTENSION OF SERIES A FINANCING TO 82M€ TO ENSURE BROAD DEVELOPMENT OF FIRST-IN-CLASS ADC PIPELINE Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful…

Lava Therapeutics completes $83M Series C round lead by Novo Holdings and Sanofi Ventures, and also followed up by Ysios, Redmile Biopharma, BB Pureos and current shareholders

Inversión, Venture Capital

18/09/2020 Press release LAVA THERAPEUTICS ANNOUNCES $83 MILLION SERIES C FINANCING TO ADVANCE NOVEL IMMUNO-ONCOLOGY PROGRAMS.     Funding to support advancement of powerful bispecific gamma-delta T cell engager programs for the treatment of a broad range of cancers New investors include Novo Holdings, Sanofi Ventures, Redmile, Ysios and BB Pureos Utrecht, The Netherlands and…